Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Anti-BCMA CAR-T Following ASCT in NDMM
NCT06913192Phase 1Not yet recruiting
- Sponsor
- Xuzhou Medical University
- Start
- Apr 2025
- Primary completion
- Feb 2027
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of anti-BCMA CAR-T in multiple myeloma (MM), sponsored by Xuzhou Medical University. Primary endpoint: Overall Response Rate at Month 24. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
anti-BCMA CAR-T
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06913192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06913192.